28 October 2024 in npj Digital Medicine
We developed and evaluated the Digital Platform for Exercise (DPEx): a decentralized, patient-centric approach designed to enhance all aspects of clinical investigation of exercise therapy. DPEx integrated provision of a treadmill with telemedicine and remote biospecimen collection permitting all study procedures to be conducted in patient’s homes. Linked health biodevices enabled high-resolution monitoring of lifestyle and physiological response. Here we describe the rationale and development of DPEx as well as feasibility evaluation in three different cohorts of patients with cancer: a phase 0a development study among three women with post-treatment primary breast cancer; a phase 0b proof-of-concept trial of neoadjuvant exercise therapy in 13 patients with untreated solid tumors; and a phase 1a level-finding trial of neoadjuvant exercise therapy in 53 men with localized prostate cancer. Collectively, our study demonstrates the utility of a fully digital, decentralized approach to conduct clinical trials of exercise therapy in a clinical population.
10 September 2026 in Cancer Epidemiology, Biomarkers & Prevention
Background: We leveraged observational data to conduct a target trial emulation (TTE) framework evaluating the association of exercise on distant disease-free survival (DDFS) in a pan-cancer cohort. Methods: To emulate a randomized controlled trial, a “historical” exercise assessment (Th) identified nonexercising [<10 metabolic equivalent of task-hours per week (MET-h/week)] patients. A repeat assessment 9 to 15 months later (T0) was used to classify patients into an exercise group (≥10 MET-h/week: increased exercise from Th) and a control group (up to 10 MET-h/week: minimal increase in exercise from Th). Kaplan–Meier methods and Cox proportional hazards models from the T0 assessment were used to estimate hazard ratios (HR) for the exercise versus control group on DDFS and overall survival (OS). Results: A total of 3,022 patients were classified into the exercise group, and 1,183 were classified into the control group. With a median follow-up of 5.2 years (interquartile range, 2.7–7 years) from T0, the 5-year DDFS was 95% [95% confidence interval (CI), 93–96] in the exercise group and 92% (95% CI, 91–94) in the control group. Compared with the control group, the adjusted HR for the exercise group was 0.80 (95% CI, 0.59–1.09; P = 0.20) for DDFS and 0.78 (95% CI, 0.55–1.11; P = 0.20) for OS. Conclusions: In this pan-cancer TTE, we estimated a potential 20% to 30% improvement in DDFS in the exercise group compared with the control. Impact: These data add to a growing body of evidence supporting the further development of exercise as a therapeutic-intent strategy in primary solid tumors.